Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trialShukui Qin, Yabing Guo, Adam C. Yopp et al.|The Lancet|2023Cited by 514
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III TrialShukui Qin, Feng Chen, Feng Bi et al.|Journal of Clinical Oncology|2021Cited by 417
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 studyFeng Bi, Jiayuan Wu, Shukui Qin et al.|European journal of medical research|2025Cited by 1